An observational study in Chronic Myeloid Leukemia, sponsored by Novartis Pharmaceuticals. Active, not recruiting at 52 sites in France. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-05-29.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 92 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive by Novartis — 9 open to participants now, 13 under way, 2 of them phase 3. Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Novartis.
Among the 92 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive by Novartis, this one is the 13th largest by enrollment of the 19 observational ones that give a count, is one of 4 that started in 2024, is one of 19 observational ones, reaches primary completion later than 2 of the 12 other live ones, and was the 78th registered.
895 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 107 are open to participants now.
Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →9 of the 92 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive by Novartis are open now, in 12 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States, Australia, Brazil and 14 more countries
Ages 1–18
Novartis Pharmaceuticals · Sites in Germany
Ages 18–100
Novartis Pharmaceuticals · Sites in China
Ages 18–99
Novartis Pharmaceuticals · Sites in Saudi Arabia
Ages 18–99
Novartis Pharmaceuticals · Sites in France
Ages 18–99
By country, each count listing its studies:
Of the 77 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 47 (61%) set no upper age limit and 19 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
92 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 26 · Phase 3 20 · Phase 4 13
First in 1999; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 201 is above the median of 135 across 148 observational studies indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Median enrollment 84 across the 63 interventional studies, 400 across the 19 observational. Of the 73 that completed or were terminated, 35 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,721 studies on the registry; 222 are open to participants now.
Of its 586 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
5 of the studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive by Novartis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06092879Novartis PharmaceuticalsAsciminib Prospective Non Interventional Study as 3rd Line Therapy or More to Treat Adult Patients With CML- CP in Real World Setting in France | 2026-12-15 |
| NCT06684964Novartis PharmaceuticalsRWE,NIS,Prospective Study for the Effectiveness, Tolerability and Adherence of Asciminib in Saudi Arabia. (ASC4REAL) | 2026-12-30 |
| NCT07454850Novartis PharmaceuticalsA Study of Patient Characteristics, Co-Morbidities, and Treatment Patterns in Chronic Myeloid Leukemia Patients in Kuwait | 2027-07-02 |
| NCT07681258Novartis PharmaceuticalsA Study of Asciminib Safety and Efficacy in Young Adults With Chronic Myeloid Leukemia in the Gulf Region | 2027-09-01 |
| NCT04925479Novartis PharmaceuticalsStudy to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia | 2027-09-03 |
Add all 5 to your calendar (.ics) → With an account.
Among the 92 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive by Novartis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to enhance the knowledge on asciminib treatment in a broader and real-life population by collecting additional data to characterize the treatment patterns of patients treated with asciminib, with a primary objective represented by maintenance on treatment at 12 months.
The ASSURE-3 study is a national, multicentric, non-interventional, prospective study in real-life conditions with primary data collection in adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) previously treated with two or more Tyrosine Kinase Inhibitors (TKIs). It will be conducted in France with hematologists, onco-hematologists, physicians with documented involvement in managing Ph+ CML-CP patients in routine practice, practicing in public or private health care institutions. Each patient will be followed during 15 months at M0, M1 and then every 3 months (rhythm of visits according to the routine clinical care), or until premature discontinuation of asciminib treatment.
Historical data will be abstracted retrospectively by the participating physicians from patient files, to collect information using an electronic case report form (eCRF). Primary data will be collected during inclusion and follow-up visits
Adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) previously treated with two or more tyrosine kinase inhibitors
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adult patients with Ph+ CML-CP previously treated with two or more tyrosine kinase inhibitors
Other: Asciminib
There is no treatment allocation. Patients administered Asciminib by prescription will be enrolled
Also known as: Scemblix
Proportion of patients remaining on asciminib at 12 months
Proportion of patients remaining on asciminib treatment at 12 months to be provided
Time frame: Month 12
Proportion of patients in major molecular response (MMR) - for patients not in MMR at treatment initiation
Molecular response to treatment: Response to treatment (MMR, BCR::ABL1 ≤ 0.1% on the International Scale, IS) at 12 months (+/- 1 month) for patients not in MMR at treatment initiation
Time frame: 12 months
Proportion of patients in MMR - for patients in MMR at treatment initiation
Molecular response to treatment: Maintenance of molecular response (MMR, BCR::ABL1 ≤ 0.1% on the International Scale, IS) at 12 months (+/- 1 month) for patients in MMR at treatment initiation
Time frame: 12 months
Proportion of patients in MR2, MMR, MR4.0, MR4.5, uMR4.5 - for all patients
Molecular response to treatment: Kinetics of response: MR2, MMR, MR4.0, MR4.5, undetectable MR4.5 for all patients. MR2, MR4, MR4.5 are defined as the transcript ratio of BCR-ABL1/ABL1 being 1% or less, 0.01% or less and 0.0032% or less respectively
Time frame: 3 months, 6 months, 9 months, 12 months and 15 months
BCR::ABL1 on the International Scale (IS) kinetics along treatment - for all patients
Kinetics of response: BCR::ABL1 on the International Scale (IS) for all patients
Time frame: 15 months
Time to MMR from the index date - for patients not in MMR at treatment initiation
Kinetics of response: Time to MMR for patients not in MMR at treatment initiation
Time frame: Up to 15 months
Time from the first MMR to the first loss of MMR - for patients not in MMR at treatment initiation
Molecular response to treatment: Duration of MMR for patients not in MMR at treatment initiation
Time frame: Up to 15 months
Event-Free Surviva (EFS)
EFS: time from index date to occurrence of one the events listed among variables: * lack of efficacy, i.e., BRC::ABL1\>1% or loss of CCyR if assessed * disease progression (CML-AP/BP, CML death) * death from any cause * definitive treatment discontinuation due to any reason
Time frame: Up to 15 months
Progression-Free Survival (PFS)
PFS: time from index date to occurrence of one of the progression markers listed among variables: * disease progression (CML-AP/BP, CML death), * death from any cause, * definitive treatment discontinuation due to any reason
Time frame: Up to 15 months
Comorbidity profile
Charlson comorbidity index (CCI) at index date
Time frame: Baseline
Disease characteristics
Disease characteristics to be provided
Time frame: Baseline
History of TKI treatment
History of TKI treatment to be provided
Time frame: Baseline
Management of patients in real-life
Concomitant medications
Time frame: 15 months
Exposure patterns to asciminib
Exposure patterns to be provided
Time frame: 15 months
EORTC QLQ-C30 (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30)
The EORTC QLQ-C30 contains 30 questions assessed by the participant. There are 9 multiple-item scales: 5 scales that assess aspects of functioning (physical, role functioning, cognitive, emotional, and social); 3 symptom scales (Fatigue, Pain, and Nausea and Vomiting); and a global health status/Quality of Life (QOL) scale. There are 5 single-item measures assessing additional symptoms (i.e., dyspnea, loss of appetite, insomnia, constipation, and diarrhea) and a single item concerning perceived financial impact of the disease. All but two questions have 4-point scales ranging from "Not at all" to "Very much." The two questions concerning global health status/ QOL have 7 point scales with ratings ranging from "Very poor" to "Excellent." For each of the 14 domains, final scores are transformed such that they range from 0-100, where higher scores indicate improvement.
Time frame: Baseline, 3months, 6months, 9months, 12months, 15months
EORTC QLQ-CML24 questionnaire
The EORTC QLQ-CML24 was designed to supplement the QLQ-C30 - the QLQ-CML24 is not a stand-alone instrument but is to be used in conjunction with the QLQ-C30. The EORTC QLQ-CML 24 is composed of four multi-item scales and two single-item scales. The module consists of 24 items assessing symptoms burden (13 items), impact on worry/mood (4 items), impact on daily life (3 items), satisfaction with care and information (2 items) body image problems (1 item) and satisfaction with social life (1 item). The items were measured on four levels: 1=not at all, 2=a little, 3=quite a bit, 4=very much. For each domain, scores were averaged and transformed to 0 to 100. A higher score in satisfaction with social life domain indicates a higher level of satisfaction. A positive change from baseline indicates increasing satisfaction.
Time frame: Baseline, 3months, 6months, 9months, 12months, 15months
Emergence of mutations
If available at end of treatment: mutational analysis, methods and results
Time frame: Up to 15 months
Proportion of patient with an AE described during asciminib treatment among patient reporting the same AE which led to discontinuation with previous TKI treatments
Cross intolerance with previous TKI treatments
Time frame: Up to 15 months
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2024 (actual). Primary completion is estimated for Dec 2026, 33 months after the start.
Of 67 observational studies under Leukemia, Myelogenous, Chronic, BCR-ABL Positive, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 103. This study's planned 33 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive →